Sequencing beats selection in international expansion
Picking the right market matters less than entering it in the right order, at the right depth, with reversal points agreed in advance.
Most expansion post-mortems blame market selection. Read closely and the market was usually defensible; the sequencing was not. The company went deep before it had evidence, hired before it had a repeatable motion, and localised before it knew which segment would pay.
Entry is not binary. Between 'ignore' and 'full subsidiary' sits a ladder: remote sales into the market, a partner-led motion, a small local team, then a full entity. Each rung buys information at a known price.
The right question is therefore not 'which market?' but 'what is the cheapest rung that produces the evidence we need to justify the next one?' That reframing routinely cuts first-year commitment by half without slowing learning.
Sequencing also forces honesty about capacity. Two markets entered at rung one usually beat one market entered at rung three, because the organisation can only absorb so much novelty at once — new buyers, new pricing, new compliance, new hires.
Finally, agree the reversal points while enthusiasm is high. If pipeline coverage in month nine is below a stated threshold, the team steps down a rung rather than arguing about whether to persevere. Pre-committed exits are far cheaper than negotiated ones.
Facing this decision now?
We produce boardroom-ready market entry decision briefs for executives committing six- or seven-figure capital to a new market.
Request a brief